PEDS Advance Access published online on December 9, 2005
Protein Engineering Design and Selection, doi:10.1093/protein/gzi074
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China
* To whom correspondence should be addressed. Glycogen synthase kinase 3 (GSK-3) inhibition is an important research topic because of its wide range of associated health implications. The interaction mode of a series of N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine compounds with human GSK-3 has been studied using molecular docking and 3D-QSAR approaches. In the 3D-QSAR studies, the molecular alignment and conformation determination are so important that they affect the success of a model. Flexible docking (AutoDock3.0.5) was used for the determination of active conformation and molecular alignment. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) were used to develop 3D-QSAR models of 80 N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine compounds. The r2 values were 0.870 and 0.861 for CoMFA and CoMSIA models, respectively. The predictive ability of these models was validated by 10 compounds of the test set. Mapping these models back to the topology of the active site of GSK-3 led to a better understanding of the vital N-phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines-GSK-3 interactions. The results demonstrate that combination of ligand-based and receptor-based modeling is a powerful approach to build 3D-QSAR models. The interaction mode from this study may be helpful for the design of a novel inhibitor and guide the selection of candidate sites for further experimental studies on site-directed mutagenesis.
Received January 3, 2005
Revised August 1, 2005
Accepted October 6, 2005
Article
Inhibitory mode of N-phenyl-4-pyrazolo[1,5-b] pyridazin-3-ylpyrimidin-2-amine series derivatives against GSK-3: molecular docking and 3D-QSAR analyses
Jingfa Xiao 1,
Zongru Guo 1 *,
Yanshen Guo 1,
Fengming Chu 1,
and
Piaoyang Sun 2
2 Jiangsu Hengrui Medicine Co., Ltd, Jiangsu, China
Zongru Guo, E-mail: zrguo{at}imm.ac.cn
![]()
Abstract ![]()
CiteULike
Connotea
Del.icio.us What's this?